Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

Despite the approval of second-generation antiobesity medications, metabolic and bariatric surgery (MBS) use among U.S.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

According to a recent study, glucagon-like peptide-1 receptor agonists are associated with a reduction in alcohol intake.

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.